

SAPH 2026

THE 19TH ANNUAL CONFERENCE OF
THE SAUDI ASSOCIATION FOR PULMONARY HYPERTENSION
12-14 FEBRUARY 2026 | JEDDAH HILTON, SAUDI ARABIA

Organized By:



In Collaboration With:



SCIENTIFIC PROGRAM



Dear Colleagues,

It gives me great pleasure to welcome you all to the 19th Annual Conference of the Saudi Association for Pulmonary Hypertension (**SAPH2026**) which will be held at Hilton Hotel, Jeddah, Saudi Arabia on 12-14 February 2026.

SAPH is maintaining the quest for development and progress year after year. **SAPH2026** aims to create a platform for regional medical professionals to engage in exchange for knowledge and expertise on the latest and best practice methods in Pulmonary Hypertension.

As a Continuation of Successful Collaboration between the Saudi Association for Pulmonary Hypertension (**SAPH**) and the Pulmonary Vascular Research Institute (PVRI), it has been proven that it is highly successful and helped in introducing physicians in The Middle East and North African countries to the world experts in the field of Pulmonary Hypertension and to the most advanced developments in understanding and managing Pulmonary Hypertension.

The Scientific Committee is planning a comprehensive Scientific Program covering all aspects of Pulmonary Vascular Diseases in both Adult & Children, from the basics of Pathobiology and Pathophysiology, Diagnosis, Classification and Management to the most advanced development in Therapies and Interventional Modalities.

The program will be covered by the internationally recognized leaders in the field of Pulmonary Hypertension.

We are much appreciative to all our distinguished speakers and chairpersons. My hope is that all those who are practicing physicians will make an effort to attend and benefit from this Conference.

With my best regards,



Prof. Abdullah M. Aldalaan, MD

Chairman, the 19th Annual Conference of Saudi Association for Pulmonary Hypertension (SAPH2026)
Chairman, Saudi Association for Pulmonary Hypertension (SAPH)
Consultant, Pulmonary Medicine
Director, Pulmonary Hypertension Program, Lung Health Center
King Faisal Specialist Hospital & Research Centre
Professor of Medicine, Alfaisal University
Riyadh, Saudi Arabia



DAY 1 - THURSDAY

12 FEBRUARY 2026

EVENING SESSION

Pre-Conference Workshops

15:00 - 16:00 **Comprehensive Multimodality Imaging Findings in PH/ CTEPH**

Speaker:  Mnahi Bin Saeedan

Chair & Discussant:  Sarah K. Alrasheed

16:00 - 17:00 **Right Heart Catheterization; State of the Art Measurements**

Speaker:  Stephan Rosenkranz

Chair & Discussant:  Abdullah A. Al Masoud

17:00 - 18:00 **Risk Stratification and Management; Case-Based Scenarios**

Speaker:  Sean Gaine

Chair & Discussant:  Nawal A. Al Gubaisi

DAY 1 - THURSDAY

12 FEBRUARY 2026

EVENING SESSION

17:00 - 18:45 **REGISTRATION**

18:45 - 19:00 **Welcome Notes**

 Prof. Abdullah M. Aldalaan

Session 1: Keynote

Chairs:  Abdullah M. Alkhodair

 Saleh A. Aldammas

19:00 - 19:30 **TGF- β Super family and PDGF Pathways Story: Origins, Breakthroughs, and Future Direction**

 Paul Yu

19:30 - 20:00 **PH: Year in Review, Key Milestones and Advances**

 Husam M. Sakkijha

20:00 - 20:10 **Q & A Panel Discussion**

20:10 - 20:30 **SAPH International Collaborating Societies Greetings**



EAST ASIAN SOCIETY OF
PULMONARY HYPERTENSION
(EASOPH)

Prof. Luke Howard, MD, DPhil, FRCP

PVRI Co-Lead, Innovative Drug Discovery Initiative



Prof. Zhi-Cheng Jing, MD, PhD

President, East Asian Society of Pulmonary Hypertension



Prof. Yoshihiro Fukumoto, MD, PhD, FJCC, FESC, FAHA, FJCS

President, Japanese Pulmonary Circulation and Pulmonary Hypertension Society



Prof. Chih-Hsin Hsu, MD, PhD

President, Taiwan Society of Critical Care Medicine

20:30 - 22:30 **DINNER**

END OF 1ST DAY

DAY 2 - FRIDAY

13 FEBRUARY 2026

MORNING SESSION

07:30 - 08:15 REGISTRATION

Session 2: PAH Basic Science

Chairs:	🇸🇦 Abdullah M. Aldalaan	🇺🇸 Mona Alotaibi
08:20 - 08:40	Unraveling the Genetic and Epigenetic Blueprint of PAH	🇩🇪 Soni Pullamessati
08:40 - 09:00	Deep Phenotyping; Endophenotypes-Based Ontology	🇺🇸 Mona Alotaibi
09:00 - 09:20	GDF2 Gene Mutation in High-Inbred Population with PAH	🇸🇦 Lama A. Alabdi
09:20 - 09:30	Q & A Panel Discussion	

09:30 - 09:45 COFFEE BREAK

Session 3: PAH Management ; TGF-β Super Family Pathway

Chairs:	🇩🇪 Stephan Rosenkranz	🇨🇳 Zhi-Cheng Jing
09:45 - 10:05	Sotatercept in Newly Diagnosed PAH; Efficacy and Safety; (HYPERION Study)	🇩🇪 H. Ardeschir Ghofrani
10:05 - 10:25	Sotatercept Longterm Efficacy & Safety in PAH; SOTERIA Study	🇺🇸 Ioana Preston
10:25 - 10:45	Targeting the Activin Signaling Pathway in Cpc-PH due to HFrEF	🇫🇷 Jean Luc Vachier
10:45 - 11:00	Q & A Panel Discussion	
11:00 - 11:20	Satellite Symposium Driving Right (Right Ventricle, Right Outcomes): A Data-Driven Perspective on Riociguat Effect on RV Function in PAH and CTEPH	🇩🇪 H. Ardeschir Ghofrani

11:20 - 13:30 PRAYER AND LUNCH BREAK



DAY 2 - FRIDAY

13 FEBRUARY 2026

AFTERNOON SESSION

Session 4: Pulmonary Arterial Hypertension Treatment (Miscellaneous)

Chairs:	🇮🇹 Roberto Badagliacca	🇺🇸 Paul Yu
13:30 - 13:50	Targeting Smad 2/3 Signaling Pathway; A Potential Therapeutic Molecule with less side effect (ALG-801)	🇺🇸 HQ Han
13:50 - 14:10	Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with PAH	🇧🇪 Jean Luc Vachier
14:10 - 14:30	Insights from PATH-GCC: PAH Treatment Patterns and Outcomes Across the Gulf Countries	🇸🇦 Majdy M. Idrees
14:30 - 14:50	Exploring Novel Targets for the Next Generation of PAH Therapies	🇫🇷 Marc Humbert
14:50 - 15:00	Q & A Panel Discussion	

15:00 - 15:30 COFFEE BREAK

Session 5: Challenging Real-life Cases

Chairs:	🇸🇦 Shaya Al Shaya	🇯🇵 Yoshihiro Fukumoto	🇮🇹 Sean Gaine
15:30 - 15:50	PAH with Catastrophic Course with the Whole Spectrum of Intervention	🇸🇦 Noura Alturaif	
15:50 - 16:10	A Rare Case of Subacute PAH	🇸🇦 Fayed K. Al Ahmadi	
16:10 - 16:30	Cough and "Severe ILD "; A Case of Unexplained Progressive Dyspnea	🇸🇦 Hani Sabour	
16:30 - 16:50	Multifactorial Hemoptysis: A Case Unraveled.	🇸🇦 Ragdah Arif	

END OF 2nd DAY

DAY 3 - SATURDAY

14 FEBRUARY 2026

MORNING SESSION

Session 6: Pulmonary Hypertension Management (Focus on Group III)

Chairs:  Bader J. Alghamdi

09:00 – 09:20 **PH Associated with CLD; RHC- Based timely Diagnosis and Role of Screening in PH-ILD**

 David Kiely

09:20 – 09:40 **PH- ILD; Contemporary Management**

 Luke Howard

09:40 - 10:00 **Inhaled Seralutinib in PH-ILD Treatment; a Potential Two Targets in One**

 Khodr Tello

10:00 - 10:20 **Tyrosine Kinase Inhibitors in PAH: a Double-Edged Sword**

 Olivier Sitbon

10:20 - 10:30 **Q & A Panel Discussion**

10:30 - 10:45 COFFEE BREAK

 Hassan Nuaimat

DAY 3 - SATURDAY

14 FEBRUARY 2026

MORNING SESSION

Session 7: CTEPH

Chairs:  Bader Alzahrani

 Khalid Alobeidellah

10:45 - 11:05 **Ten-year survival and prognostic factors after BPA in inoperable CTEPH**

 Hiromi Matsubara

11:05 - 11:25 **Optimizing BPA Outcomes: An Update on The Role of Medical Therapy Pre- and Post-Procedure**

 Irene Lang

11:25 - 11:45 **Enhancing the Diagnostic Approach to CTEPH**

 David Kiely

11:45 - 12:10 **Balloon Pulmonary Angioplasty in Sickle Cell Disease with Chronic Thromboembolic Pulmonary Hypertension**

 Ali Omar Abualsaud

12:10 - 12:20 **Q & A Panel Discussion**

12:20 - 12:30 CLOSING REMARKS

12:30 - 13:30 LUNCH

END OF 3rd DAY

CONTACT:



Email: saphsts@gmail.com

© Saudi Association for Pulmonary Hypertension/ Saudi Thoracic Society, All Rights Reserved.